Supporting new Hepatitis treatment for genotype 3
Yesterday, Haemophilia Scotland made a patient organisation submission to the Scottish Medicines Consortium in support of the application from Gilead to extend the approval of their Harvoni, direct acting antiviral, treatment for Hepatitis C.
The product already has SMC approval for the treatment of people with genotypes 1 and 4. If successful the current application would extend its use to genotype 3. Although several direct acting antivirals have already got SMC approval, this would be the first product approved for genotype 3. SMC approval gives Scotland’s 14 Regional Health Boards permission to use a product.
People with a bleeding disorder and Hepatitis C in Scotland have been very successful in getting access to the new treatments. We are only aware of a couple of cases where there have been problems and are working on those with the Scottish Government. Shona Robison MSP, Cabinet Secretary for Health, Wellbeing, and Sport has said that,
it is very important that those who have been affected through the infected blood and blood products are given the opportunity to have those treatments, but they have to be clinically suitable.
If you are trying to get access to treatment and experience any problems then please get in touch.